source
- Revolution Medicines reports promising early data for KRAS drug combo, plans Phase 3 in pancreatic cancerRevolution Medicines presented early-stage results that support moving forward with a Phase 3 study of a combination of two KRAS-targeted agents in pancreatic cancer. The data, shown for the first…
- Otsuka presents long-term Phase 3 data for Voyxact, aiming to secure full FDA approval for kidney diseaseOtsuka announced new long-term results from the Phase 3 trial of its kidney disease drug Voyxact. The data show that the therapy stabilized kidney function over an extended period, building on ear…